The course of treatment and the success rate is dependent on the type of<unk> A. Some patients with atypical HUS and TTP have responded to plasma infusions or exchanges, a procedure which replaces proteins necessary for the complement cascade that the patient does not have; however, this is not a permanent solution or treatment, especially for patients with congenital predispositions. Monoclonal antibodies like eculizumab and caplacizumab can assist with atypical hemolytic uremic syndrome and acquired<unk>  thrombocytopenic purpura respectively whilst dexamethasone can help with immune<unk>  thrombocytopenic purpura and low molecular weight heparin can help with disseminated intravascular coagulation.
Thrombotic microangiopathy
Systemic vasculitis
Cryoglobulinemic vasculitis
Lupus vasculitis
Venom-induced consumption coagulopathy
Cerebral vasculitis
Primary fibrinogenolysis
Amyloid purpura